124 related articles for article (PubMed ID: 346616)
1. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
Lisch HJ; Patsch J; Sailer S; Braunsteiner H
Atherosclerosis; 1975; 21(3):391-9. PubMed ID: 1148032
[TBL] [Abstract][Full Text] [Related]
3. The metabolic spectrum of halofenate.
Ryan JR
Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
[TBL] [Abstract][Full Text] [Related]
4. One-year trials with halofenate, clofibrate, and placebo.
Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
Krut LH; Seftel HC; Joffe BI
S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
[TBL] [Abstract][Full Text] [Related]
6. A two-year crossover therapeutic trial with halofenate and clofibrate.
Dujovne CA; Azarnoff DL; Pentikainen P; Manion C; Hurwitz A; Hassanein K
Am J Med Sci; 1976; 272(3):277-84. PubMed ID: 797258
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
Jain AK; Ryan JR; McMahon FG
N Engl J Med; 1975 Dec; 293(25):1283-6. PubMed ID: 171574
[TBL] [Abstract][Full Text] [Related]
8. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
Rees ED; Hamilton RD; Kanner IF; Wasson S; Hearn T
Atherosclerosis; 1976 Sep; 24(3):537-46. PubMed ID: 788722
[TBL] [Abstract][Full Text] [Related]
9. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
[No Abstract] [Full Text] [Related]
10. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Keller C; Wolfram G; Zöllner N
Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
[TBL] [Abstract][Full Text] [Related]
11. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
[No Abstract] [Full Text] [Related]
12. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
[No Abstract] [Full Text] [Related]
13. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
[TBL] [Abstract][Full Text] [Related]
14. [Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
Kuntzen O; Hehl FJ; Walter E; Zimmermann R
Arzneimittelforschung; 1978; 28(12):2349-52. PubMed ID: 227420
[TBL] [Abstract][Full Text] [Related]
15. Effect of halofenate on serum uric acid.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
[No Abstract] [Full Text] [Related]
16. Studies on the mechanism of action of halofenate.
Mandel LR
Lipids; 1977 Jan; 12(1):34-43. PubMed ID: 319318
[TBL] [Abstract][Full Text] [Related]
17. Altered insulin and glucagon secretion in treated genetic hyperlipemia: a mechanism of theraphy?
Eaton RP; Oase R; Schade DS
Metabolism; 1976 Mar; 25(3):245-9. PubMed ID: 1250161
[TBL] [Abstract][Full Text] [Related]
18. Hepatic triglyceride lipases--effect of clofibrate and halofenate.
Cenedella RJ
Biochem Pharmacol; 1976 Dec; 25(23):2657-61. PubMed ID: 10929
[No Abstract] [Full Text] [Related]
19. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Hutchison JC; Wilkinson WH
Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
[No Abstract] [Full Text] [Related]
20. Potentiation of hypoglycemic effect of chlorpropamide and phenfromin by halofenate.
Kudzma DJ; Friedberg SJ
Diabetes; 1977 Apr; 26(4):291-5. PubMed ID: 321288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
